Biochemical and Biophysical Research Communications
Production and characterization of monoclonal antibody against a triple negative breast cancer cell line
Introduction
Due to rising cancer incidence over the time, its global importance is undeniable. Breast cancer is the most prevalent malignancy among women around the world such that more than 1,400,000 new cases are being diagnosed annually. This disease is caused by a combination of genetic and environmental factors. Despite immense studies over many years on diagnosis and treatment for breast cancer, about 30% of treated patients will relapse and require subsequent therapy [1,2].
Since the identification of new disease-specific biomarkers can accelerate the drug discovery, many studies have been conducted in order to identify biomarkers as new targets for effective diagnosis and cancer therapy. Nowadays, several tumor markers are being utilized for screening, staging, prognosis, treatment, and surveillance of breast cancer including Carcinoembryonic antigen (CEA), CA 15–3, CA 27.29, Estrogen receptor (ER), Progesterone receptor (PR), Human epidermal growth factor receptor 2 (HER2), Plasminogen activator inhibitor1 (PAI-1), and Urokinase plasminogen activator (uPA) [3,4].
During the past decades, genomics and proteomics techniques have introduced an enormous number of candidate tumor-associated antigens. Since the alternative splicing of mRNA, along with post-translational modifications, causes each gene to give rise to different possible protein products, many of targets cannot be simply recognized by genomic approaches. In addition, there are many context-dependent cancer-specific epitopes that are only presented on the whole living cell in the context of other membrane-associated macromolecules. Identification of these epitopes by genomics-based and proteomics-based approaches involves high difficulty. Therefore, other techniques must be used to identify these cancer-related antigens [5,6].
The monoclonal antibody-based technologies provide an approach to complete genomics and proteomics attempts in which intact cells are used as a source of antigens for detection of cancer-specific cell surface targets. With this technology, a panel of monoclonal antibodies (mAbs) with a high level of epitope diversity is produced [7].
In the present study, hybridoma cells were produced by immunizing mice with a Pari-ICR cell line obtained from one patient with breast cancer. MAb that reacted with a surface antigen of immunizing cell line, but not normal cells, was selected and the target was identified by immunoprecipitation and mass spectrometry.
Section snippets
Cell culture
Cancer cell lines (MDA-MB-231, MCF-7, SKOV3, MIA-PaCa-2, MDA-MB-468, PaTu 8902, and mehr80) and normal human fibroblast were purchased from National cell Bank of Iran based in Iran Pasture Institute; ASCs were extracted from breast adipose tissues of healthy donor with cosmetic mammoplasty surgery after obtaining written informed consent and characterized as described before [8]. The cells were cultured at 37 °C in a humidified atmosphere of 5% CO2. Normal human fibroblast and ASC were cultured
Generation and selection of mouse monoclonal antibodies against Pari-ICR cell line
In this study, a new established triple negative breast cancer cell line (Pari-ICR) isolated from the primary breast tumor of a 36 years old patient with grade II invasive ductal carcinoma was used for immunization. The mouse showing the highest titer was sacrificed and splenocytes were fused with SP2/0 cells for hybridoma production. After fusion, screening of growing hybridomas was performed by flow cytometry. According to the obtained results, 5 out of 78 antibody-producing hybridomas showed
Discussion
Breast cancer, one of the most controversial malignancy, is the second most common type of cancer after lung cancer (10.4% of all cancer incidence, both sexes counted), for which no significant progress in prognosis and patient survival has been reported [9,10]. Therefore, the discovery of other potential biomarkers that can predict tumor behavior is of great importance in breast cancer. The antibody-based approach provides an opportunity to find out new targets and target epitopes with
Conclusion
Using the antibody-based strategy, we identified NCAM1 as a potential therapeutic target and biomarker for breast cancer. Monoclonal Anti-NCAM1 antibody that was produced in our laboratory is suitable for Western blotting, flow cytometry, and immunohistochemical analyses. The produced monoclonal antibody may be against a novel epitope of NCAM1. In order to evaluate the specificity of the antibody, we need screening more normal and cancer tissues. Additionally, since there are specific breast
Acknowledgments and funding
This work was financially supported by a grant from Shiraz university of Medical Sciences (grant number: 94-7652) and in part by Shiraz Institute for Cancer research (grant number: ICR-100-508).
References (28)
- et al.
Clinical use of biomarkers in breast cancer: updated guidelines from the european group on tumor markers (EGTM)
Eur. J. Canc.
(2017) - et al.
Antibody-based identification of cell surface antigens: targets for cancer therapy
Curr. Opin. Pharmacol.
(2008) - et al.
Phenotypic screening: the future of antibody discovery
Drug Discov. Today
(2016) - et al.
Phenotypic screening-the fast track to novel antibody discovery
Drug Discov. Today Technol.
(2017) - et al.
Expression profile of IL-8 and growth factors in breast cancer cells and adipose-derived stem cells (ASCs) isolated from breast carcinoma
Cell. Immunol.
(2010) Tumor markers of breast cancer: new prospectives
J. Oncol. Sci.
(2017)- et al.
Mast cells in breast cancer angiogenesis
Crit. Rev. Oncol. Hematol.
(2017) - et al.
Specific detection of CD56 (NCAM) isoforms for the identification of aggressive malignant neoplasms with progressive development
Am. J. Pathol.
(2009) - et al.
Fundamentals of NCAM expression, function, and regulation of alternative splicing in neuronal differentiation
- et al.
Targeting the neural cell adhesion molecule in cancer
Canc. Lett.
(2007)
Molecular markers for breast cancer: prediction on tumor behavior
Dis. Markers
Biological markers of invasive breast cancer
Jpn. J. Clin. Oncol.
Organ specific tumor markers: what's new?
Indian J. Clin. Biochem.
Monoclonal antibodies: producing magic bullets by somatic cell hybridization
J. Immunol.
Cited by (10)
Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis
2023, Medicine (United States)Translational Research for Identifying Potential Early-stage Prostate Cancer Biomarkers
2023, Cancer Genomics and ProteomicsA novel seven-gene panel predicts the sensitivity and prognosis of head and neck squamous cell carcinoma treated with platinum-based radio(chemo)therapy
2021, European Archives of Oto-Rhino-Laryngology